Argo Biopharma Advances Factor XI siRNA Therapy into Phase I Trials
Event summary
- Argo Biopharma dosed the first participant in its Phase I trial of BW-41012, an siRNA therapy targeting Factor XI for thromboembolic diseases.
- The study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) trial in healthy volunteers in Australia.
- BW-41012 is the eighth clinical candidate from Argo's RNAi pipeline.
- Argo received IND approval from China’s NMPA for BW-41012 this month.
The big picture
Argo Biopharma’s entry into Phase I trials for BW-41012 underscores the growing interest in Factor XI as a therapeutic target for thromboembolic diseases, offering a potential alternative to existing anticoagulants with reduced bleeding risks. The company’s expanding RNAi pipeline positions it competitively in the cardiovascular and rare disease spaces, though execution across multiple candidates will be critical.
What we're watching
- Clinical Progress
- The pace at which BW-41012 demonstrates safety and efficacy in Phase I will determine its path to later-stage trials.
- Regulatory Strategy
- Whether Argo can leverage NMPA approval to accelerate global development, particularly in key markets like China and the U.S.
- Pipeline Execution
- How Argo balances advancement of BW-41012 alongside its other seven clinical-stage RNAi candidates.
Related topics